Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Mayr-Melnhof Group in connection with its acquisition of Eson Pac
Mandate

Vinge has advised Mayr-Melnhof Group in connection with its acquisition of Eson Pac

April 11, 2022 Banking and Finance Commercial Agreements Intellectual Property M&A Corporate Crime & Compliance IT, Telecommunications and Outsourcing Real Estate and Construction Environmental Law

Eson Pac are packaging specialists providing solutions for the pharma packaging supply chain. Mayr-Melnhof Group (“MM”) has acquired 100% of the shares in Eson Pac from the majority shareholder Nalka Invest AB as well as the founding family and management minority shareholders. MM is Europe’s leading producer of cartonboard and folding cartons as well as kraft papers and uncoated fine papers.

Vinge’s team consisted of Matthias Pannier, Ulrich Ziche, Måns Håkanson and Elias Bohlin (M&A), Felix Möller and Ellen Flygt (Banking and Finance), Elin Broman and Emil Lindwall (Employment), Michael Montner (IP), Mario Saad (Commercial Agreements), Mika Jordan (IT), Tove Tullberg (Compliance), Frida Ställborn (Real Property), Johan Cederblad and Lina Österberg (Environmental law).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025